BIOVICA INTL. SK-07
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more
BIOVICA INTL. SK-07 (9II) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOVICA INTL. SK-07 (9II) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOVICA INTL. SK-07 - Net Assets Trend (None–None)
This chart illustrates how BIOVICA INTL. SK-07's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOVICA INTL. SK-07 (None–None)
The table below shows the annual net assets of BIOVICA INTL. SK-07 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOVICA INTL. SK-07's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOVICA INTL. SK-07 Competitors by Market Cap
The table below lists competitors of BIOVICA INTL. SK-07 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GMO INTERNET - Dusseldorf Stock Exchang
DU:IQ3
|
$153.35K |
|
Optegra Ventures Inc.
V:OPTG
|
$153.49K |
|
American Financial Group AFGE
NYSE:AFGE
|
$153.49K |
|
Daelim Industrial Co. Ltd. Pfd. Series 1
KQ:000215
|
$153.66K |
|
Sparta Infra Cdi Fd De Invest Em Cotas De Fd Incentivados De Inv Em Infraestrutura Renda Fixa Cr Pri
SA:CDII11
|
$153.27K |
|
LTMT11
SA:LTMT11
|
$153.24K |
|
Sydinv HøjrenteLande A DKK Akk
CO:SYIHRLADKKAKK
|
$153.14K |
|
Textmunication Holdings Inc
PINK:KOAN
|
$153.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOVICA INTL. SK-07's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOVICA INTL. SK-07's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOVICA INTL. SK-07 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOVICA INTL. SK-07's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOVICA INTL. SK-07 (9II) | €- | N/A | N/A | $153.29K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |